{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:31Z","timestamp":1787020591311,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    resistance against artemisinin has not emerged in Africa; however, there are reports of the presence of polymerase chain reaction-determined residual submicroscopic parasitaemia detected on day 3 after artemisinin-based combination therapy (ACT). These residual submicroscopic parasites are thought to represent tolerant\/resistant parasites against artemisinin, the fast-acting component of the combination. This review focused on residual submicroscopic parasitaemia, what it represents, and its significance on the emergence and spread of artemisinin resistance in Africa. Presence of residual submicroscopic parasitemia on day 3 after treatment initiation leaves question on whether successful treatment is attained with ACT. Thus there is a need to determine the potential public health implication of the PCR-determined residual submicroscopic parasitaemia observed on day 3 after ACT. Robust techniques, such as in vitro cultivation, should be used to evaluate if the residual submicroscopic parasites detected on day 3 after ACT are viable asexual parasites, or gametocytes, or the DNA of the dead parasites waiting to be cleared from the circulation. Such techniques would also evaluate the transmissibility of these residual parasites.\n                  <\/jats:p>","DOI":"10.1186\/s12936-020-03235-3","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T13:07:05Z","timestamp":1587474425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of residual submicroscopic Plasmodium falciparum parasites 3 days after initiation of treatment with artemisinin-based combination therapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Richard","family":"Mwaiswelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Ngasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"3235_CR1","volume-title":"World Malaria Report 2005","author":"WHO","year":"2005","unstructured":"WHO. World Malaria Report 2005. Geneva: World Health Organization; 2005."},{"key":"3235_CR2","volume-title":"World Malaria Report 2010","author":"WHO","year":"2010","unstructured":"WHO. World Malaria Report 2010. Geneva: World Health Organization; 2010."},{"key":"3235_CR3","volume-title":"World Malaria Report 2017","author":"WHO","year":"2017","unstructured":"WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017."},{"key":"3235_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12916-018-1243-z","volume":"17","author":"A Bj\u00f6rkman","year":"2019","unstructured":"Bj\u00f6rkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, et al. From high to low malaria transmission in Zanzibar\u2014challenges and opportunities to achieve elimination. BMC Med. 2019;17:14.","journal-title":"BMC Med."},{"key":"3235_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"A Dondorp","year":"2009","unstructured":"Dondorp A, Nosten F, Das D, Phyo AP, Tarning J, Lwin KM, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"3235_CR6","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1086\/657120","volume":"51","author":"H Noedl","year":"2010","unstructured":"Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82\u20139.","journal-title":"Clin Infect Dis"},{"key":"3235_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"E Ashley","year":"2014","unstructured":"Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3235_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"3235_CR9","doi-asserted-by":"publisher","first-page":"e1001823","DOI":"10.1371\/journal.pmed.1001823","volume":"12","author":"LJ White","year":"2015","unstructured":"White LJ, Flegg JA, Phyo AP, Wiladpai-ngern JH, Bethell D, Plowe C, et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med. 2015;12:e1001823.","journal-title":"PLoS Med."},{"key":"3235_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrmicro2331","volume":"8","author":"AM Dondorp","year":"2010","unstructured":"Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272\u201380.","journal-title":"Nat Rev Microbiol"},{"key":"3235_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.febslet.2011.04.042","volume":"585","author":"I Petersen","year":"2011","unstructured":"Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. Fed Eur Biochem Soc Lett. 2011;585:1551\u201362.","journal-title":"Fed Eur Biochem Soc Lett."},{"key":"3235_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1590\/0037-8682-0098-2013","volume":"46","author":"NA Ajayi","year":"2013","unstructured":"Ajayi NA, Ukwaja KN. Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases. Rev da Soc Bras Med Trop. 2013;46:525\u20137.","journal-title":"Rev da Soc Bras Med Trop."},{"key":"3235_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"},{"key":"3235_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/infdis\/jiu467","volume":"211","author":"SM Taylor","year":"2015","unstructured":"Taylor SM, Parobek CM, Deconti DK, Kayentao K, Coulibaly SO, Meshnick SR, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680\u20138.","journal-title":"J Infect Dis"},{"key":"3235_CR15","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-saharan Africa. J Infect Dis. 2015;211:1352\u20135.","journal-title":"J Infect Dis"},{"key":"3235_CR16","volume-title":"World Malaria Report","author":"WHO","year":"2015","unstructured":"WHO. World Malaria Report. Geneva: World Health Organization; 2015."},{"key":"3235_CR17","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/infdis\/jit431","volume":"208","author":"KB Beshir","year":"2013","unstructured":"Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis. 2013;208:2017\u201324.","journal-title":"J Infect Dis"},{"key":"3235_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1475-2875-10-380","volume":"10","author":"AM Carlsson","year":"2011","unstructured":"Carlsson AM, Ngasala BE, Dahlstr\u00f6m S, Membi C, Veiga IM, Rombo L, et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J. 2011;10:380.","journal-title":"Malar J."},{"key":"3235_CR19","doi-asserted-by":"publisher","first-page":"26330","DOI":"10.1038\/srep26330","volume":"6","author":"H Chang","year":"2016","unstructured":"Chang H, Meibalan E, Zelin J, Daniels R, Eziefula AC, Meyer EC, et al. Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda. Sci Rep. 2016;6:26330.","journal-title":"Sci Rep."},{"key":"3235_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12936-015-1018-3","volume":"14","author":"K Kiaco","year":"2015","unstructured":"Kiaco K, Teixeira J, Machado M, do Ros\u00e1rio V, Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and k13-propeller polymorphisms in Luanda, Angola. Malar J. 2015;14:504.","journal-title":"Malar J."},{"key":"3235_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4269\/ajtmh.18-0729","volume":"100","author":"R Mwaiswelo","year":"2019","unstructured":"Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larson E, Malmberg M, et al. Prevalence of and risk factors associated with polymerase chain reaction-determined Plasmodium falciparum positivity on day 3 after initiation of artemether\u2013lumefantrine treatment for uncomplicated malaria in Bagamoyo district, Tanzania. Am J Trop Med Hyg. 2019;100:1179\u201386.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40249-016-0227-5","volume":"6","author":"R Abdul-Ghani","year":"2017","unstructured":"Abdul-Ghani R, Mahdy MAK, Beier JC, Basco LK. Hidden reservoir of resistant parasites: the missing link in the elimination of falciparum malaria. Infect Dis Poverty. 2017;6:12.","journal-title":"Infect Dis Poverty."},{"key":"3235_CR23","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"3235_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis."},{"key":"3235_CR25","doi-asserted-by":"publisher","first-page":"970","DOI":"10.4269\/ajtmh.18-0233","volume":"99","author":"JM Roth","year":"2018","unstructured":"Roth JM, Sawa P, Omweri G, Makio N, Osoti V, De Jong MD, et al. Molecular detection of residual parasitemia after pyronaridine\u2013artesunate or artemether\u2013lumefantrine treatment of uncomplicated Plasmodium falciparum malaria in Kenyan Children. Am J Trop Med Hyg. 2018;99:970\u20137.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 1","key":"3235_CR26","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","volume":"8","author":"A Djimd\u00e9","year":"2009","unstructured":"Djimd\u00e9 A, Lef\u00e8vre G. Understanding the pharmacokinetics of Coartem. Malar J. 2009;8(Suppl 1):S4.","journal-title":"Malar J."},{"key":"3235_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White N. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697\u2013704.","journal-title":"Antimicrob Agents Chemother"},{"key":"3235_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1046\/j.1365-2125.1998.00830.x","volume":"46","author":"F Ezzet","year":"1998","unstructured":"Ezzet F, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether\u2009+\u2009benflumetol) in malaria patients. Br J Clin Pharmacol. 1998;46:553\u201361.","journal-title":"Br J Clin Pharmacol"},{"key":"3235_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.1155165","volume":"320","author":"NJ White","year":"2008","unstructured":"White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330\u20134.","journal-title":"Science"},{"key":"3235_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-017-1731-1","volume":"16","author":"NJ White","year":"2017","unstructured":"White NJ. Malaria parasite clearance. Malar J. 2017;16:88.","journal-title":"Malar J"},{"key":"3235_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11908-010-0099-y","volume":"12","author":"JT Lin","year":"2011","unstructured":"Lin JT. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep. 2011;12:165\u201373.","journal-title":"Curr Infect Dis Rep."},{"issue":"Suppl 1","key":"3235_CR32","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1186\/1475-2875-7-S1-S8","volume":"7","author":"NJ White","year":"2008","unstructured":"White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J. 2008;7(Suppl 1):S8.","journal-title":"Malar J."},{"key":"3235_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijpddr.2012.03.004","volume":"2","author":"CH Sibley","year":"2012","unstructured":"Sibley CH, Price RN. Monitoring antimalarial drug resistance: applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist. 2012;2:126\u201333.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"3235_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/1475-2875-10-278","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. The parasite clearance curve. Malar J. 2011;10:278.","journal-title":"Malar J."},{"key":"3235_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-015-0445-x","volume":"13","author":"WWARN","year":"2015","unstructured":"WWARN. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212.","journal-title":"BMC Med."},{"key":"3235_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/aje\/kwf030","volume":"156","author":"F M\u00e9ndez","year":"2002","unstructured":"M\u00e9ndez F, Mu\u00f1oz \u00c1, Carrasquilla G, Jurado D, Ar\u00e9valo-herrera M, Cortese JF, et al. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol. 2002;156:230\u20138.","journal-title":"Am J Epidemiol"},{"key":"3235_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4269\/ajtmh.2001.65.614","volume":"65","author":"RN Price","year":"2001","unstructured":"Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, et al. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg. 2001;65:614\u201322.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR38","volume-title":"Artemisinin and artemisinin-based combination therapy resistance","author":"WHO","year":"2016","unstructured":"WHO. Artemisinin and artemisinin-based combination therapy resistance. Geneva: World Health Organization; 2016."},{"key":"3235_CR39","volume-title":"Update on artemisinin resistance","author":"WHO","year":"2012","unstructured":"WHO. Update on artemisinin resistance. Geneva: World Health Organization; 2012."},{"key":"3235_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1475-2875-10-198","volume":"10","author":"W Yavo","year":"2011","unstructured":"Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J. 2011;10:198.","journal-title":"Malar J."},{"key":"3235_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J."},{"key":"3235_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12936-018-2265-x","volume":"17","author":"I Adam","year":"2018","unstructured":"Adam I, Ibrahim Y, Gasim GI. Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. Malar J. 2018;17:110.","journal-title":"Malar J."},{"key":"3235_CR43","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1093\/emph\/eov036","volume":"2016","author":"N Mideo","year":"2016","unstructured":"Mideo N, Jeffrey A, Hathaway N, Ngasala B, Saunders D, Lon C, et al. A deep-sequencing tool for partitioning clearance rates following antimalarial treatment in polyclonal infections. Evol Med Public Health. 2016;2016:e1093.","journal-title":"Evol Med Public Health."},{"key":"3235_CR44","volume-title":"WHO Evidence Review Group on malaria submicroscopic infections 2017","author":"A Bosman","year":"2017","unstructured":"Bosman A, Cunningham J. WHO Evidence Review Group on malaria submicroscopic infections 2017. Geneva: World Health Organization; 2017."},{"key":"3235_CR45","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/infdis\/jit082","volume":"207","author":"TM Lopera-Mesa","year":"2013","unstructured":"Lopera-Mesa TM, Doumbia S, Chiang S, Zeituni AE, Konate DS, Doumbouya M, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis. 2013;207:1655\u201363.","journal-title":"J Infect Dis"},{"key":"3235_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4269\/ajtmh.2012.12-0058","volume":"87","author":"AW Maiga","year":"2012","unstructured":"Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87:23\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, et al. Adding a single low-dose of primaquine (0.25\u00a0mg\/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial. Malar J. 2016;15:316.","journal-title":"Malar J."},{"key":"3235_CR48","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/infdis\/jiu358","volume":"210","author":"G Henriques","year":"2014","unstructured":"Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis. 2014;210:2001\u20138.","journal-title":"J Infect Dis"},{"key":"3235_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4269\/ajtmh.2003.69.558","volume":"69","author":"A Djimd\u00e9","year":"2003","unstructured":"Djimd\u00e9 A, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69:558\u201363.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR50","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1128\/AAC.00481-15","volume":"59","author":"IM Hastings","year":"2015","unstructured":"Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother. 2015;59:6428\u201336.","journal-title":"Antimicrob Agents Chemother"},{"key":"3235_CR51","volume-title":"World Malaria Report 2016","author":"WHO","year":"2016","unstructured":"WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016."},{"key":"3235_CR52","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4269\/ajtmh.16-0780","volume":"97","author":"R Mwaiswelo","year":"2017","unstructured":"Mwaiswelo R, Ngasala B, Gil JP, Malmberg M, Jovel I, Xu W, et al. Sustained high cure rate of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria after 8\u00a0years of its wide-scale use in Bagamoyo district, Tanzania. Am J Trop Med Hyg. 2017;97:526\u201332.","journal-title":"Am J Trop Med Hyg."},{"key":"3235_CR53","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.1128\/AAC.02746-14","volume":"58","author":"K Thriemer","year":"2014","unstructured":"Thriemer K, Van Hong N, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with dihydroartemisini-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58:7049\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"3235_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12936-016-1240-7","volume":"15","author":"KM Tun","year":"2016","unstructured":"Tun KM, Jeeyapant A, Imwong M, Thein M, Soe S, Aung M, et al. Parasite clearance rates in upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J. 2016;15:185.","journal-title":"Malar J."},{"key":"3235_CR55","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3235_CR56","volume-title":"Artemisinin resistance and artemisinin-based combination therapy efficacy","author":"WHO","year":"2018","unstructured":"WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018."},{"key":"3235_CR57","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1128\/AAC.05102-11","volume":"55","author":"NB Gadalla","year":"2011","unstructured":"Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011;55:5408\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"3235_CR58","volume-title":"Global report on antimalarial drug efficacy and drug resistance: 2000-2010","author":"WHO","year":"2010","unstructured":"WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva: World Health Organization; 2010."},{"key":"3235_CR59","doi-asserted-by":"publisher","first-page":"e23875","DOI":"10.1371\/journal.pone.0023875","volume":"6","author":"PE Ferreira","year":"2011","unstructured":"Ferreira PE, Holmgren G, Veiga MI, Uhlen P, Kaneko A, Gil JP. PfMDR1: mechanisms of transport modulation by functional polymorphisms. PLoS ONE. 2011;6:e23875.","journal-title":"PLoS ONE"},{"key":"3235_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1475-2875-12-103","volume":"12","author":"M Malmberg","year":"2013","unstructured":"Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance\/resistance in Bagamoyo district, Tanzania. Malar J. 2013;12:103.","journal-title":"Malar J."},{"key":"3235_CR61","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/596738","volume":"199","author":"C Sisowath","year":"2009","unstructured":"Sisowath C, Petersen I, Veiga MI, M\u00e5rtensson A, Premji Z, Bj\u00f6rkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199:750\u20137.","journal-title":"J Infect Dis"},{"key":"3235_CR62","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR63","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/infdis\/jir486","volume":"204","author":"FN Baliraine","year":"2011","unstructured":"Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis. 2011;204:1120\u20134.","journal-title":"J Infect Dis"},{"key":"3235_CR64","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.03647-14","volume":"59","author":"V Baraka","year":"2015","unstructured":"Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-ratto C, Mbonye MK. Variants by artemether-lumefantrine and dihydroartemisinin- piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015;59:734\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"3235_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijpddr.2014.07.003","volume":"4","author":"J Okombo","year":"2014","unstructured":"Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-oyier LI. Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist. 2014;4:152\u201363.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"3235_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12936-016-1095-y","volume":"15","author":"J Muwanguzi","year":"2016","unstructured":"Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malar J. 2016;15:36.","journal-title":"Malar J."},{"key":"3235_CR67","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/infdis\/jis747","volume":"207","author":"M Malmberg","year":"2013","unstructured":"Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bj\u00f6rkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842\u20137.","journal-title":"J Infect Dis"},{"key":"3235_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2379-1764.1000259","volume":"6","author":"A Asenath","year":"2018","unstructured":"Asenath A, Chebon LJ, Mitei K, Opot B, Juma DW, Nyerere A, et al. Investigation of markers of artemisinin resistance at selected intervals during the 72\u00a0h period after artemisinin based combination therapy dosing in Kisumu, western Kenya. Adv Tech Biol Med. 2018;6:2.","journal-title":"Adv Tech Biol Med."},{"key":"3235_CR69","doi-asserted-by":"publisher","first-page":"e0191922","DOI":"10.1371\/journal.pone.0191922","volume":"13","author":"V Baraka","year":"2018","unstructured":"Baraka V, Mavoko HM, Nabasumba C, Francis F, Lutumba P, Alifrangis M, et al. Impact of treatment and re-treatment with amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda. PLoS ONE. 2018;13:e0191922.","journal-title":"PLoS ONE"},{"key":"3235_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12879-016-1482-6","volume":"16","author":"E Lo","year":"2016","unstructured":"Lo E, Nguyen J, Oo W, Hemming-schroeder E, Zhou G, Yang Z. Examining Plasmodium falciparum and P vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction. BMC Infect Dis. 2016;16:154.","journal-title":"BMC Infect Dis"},{"key":"3235_CR71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4269\/ajtmh.16-0893","volume":"97","author":"FG Tadesse","year":"2017","unstructured":"Tadesse FG, Lanke K, Nebie I, Schildkraut JA, Gon\u00e7alves BP, Tiono AB, et al. Molecular markers for sensitive detection of Plasmodium falciparum asexual stage parasites and their application in a malaria clinical trial. Am J Trop Med Hyg. 2017;97:188\u201398.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4269\/ajtmh.2010.09-0630","volume":"83","author":"B P\u00f6schl","year":"2010","unstructured":"P\u00f6schl B, Waneesorn J, Thekisoe O, Chutipongvivate S, Panagiotis K. Comparative diagnosis of malaria infections by microscopy, nested PCR, and LAMP in Northern Thailand. Am J Trop Med Hyg. 2010;83:56\u201360.","journal-title":"Am J Trop Med Hyg"},{"key":"3235_CR73","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1128\/IAI.66.8.3783-3787.1998","volume":"66","author":"W Jarra","year":"1998","unstructured":"Jarra W, Snounou G. Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Infect Immun. 1998;66:3783\u20137.","journal-title":"Infect Immun"},{"key":"3235_CR74","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1128\/JCM.43.1.402-405.2005","volume":"43","author":"P Schneider","year":"2005","unstructured":"Schneider P, Wolters L, Schoone G, Schallig H, Sillekens P, Hermsen R, et al. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol. 2005;43:402\u20135.","journal-title":"J Clin Microbiol"},{"key":"3235_CR75","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0166-6851(93)90077-B","volume":"61","author":"G Snounou","year":"1993","unstructured":"Snounou G, Viriyakosol S, Xin PZ, Jarra W, Pinheiro L, Rosario VE, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol. 1993;61:315\u201320.","journal-title":"Mol Biochem Parasitol"},{"key":"3235_CR76","doi-asserted-by":"publisher","first-page":"e0120210","DOI":"10.1371\/journal.pone.0120210","volume":"10","author":"W Xu","year":"2015","unstructured":"Xu W, Morris U, Aydin-schmidt B, Msellem MI, Shakely D, Petzold M, et al. SYBR green real-time PCR-RFLP assay targeting the Plasmodium cytochrome b gene\u2014a highly sensitive molecular tool for malaria parasite detection and species determination. PLoS ONE. 2015;10:e0120210.","journal-title":"PLoS ONE"},{"key":"3235_CR77","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood.V90.5.2037","volume":"90","author":"BJ Angus","year":"1997","unstructured":"Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90:2037\u201340.","journal-title":"Blood"},{"key":"3235_CR78","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1086\/340213","volume":"10400","author":"K Chotivanich","year":"2002","unstructured":"Chotivanich K, Udomsangpetch R, Mcgready R, Proux S, Newton P, Pukrittayakamee S, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis. 2002;10400:1538\u201341.","journal-title":"J Infect Dis"},{"key":"3235_CR79","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1086\/315718","volume":"182","author":"K Chotivanich","year":"2000","unstructured":"Chotivanich K, Udomsangpetch R, Dondorp A, Williams T, Angus B, Simpson JA, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000;182:629\u201333.","journal-title":"J Infect Dis"},{"key":"3235_CR80","first-page":"16","volume":"4","author":"AL Ou\u00e9draogo","year":"2013","unstructured":"Ou\u00e9draogo AL, Guelb\u00e9ogo WM, Cohuet A, Morlais I, King JG, Gon\u00e7alves BP, et al. A protocol for membrane feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae. Malaria World J. 2013;4:16.","journal-title":"Malaria World J."},{"key":"3235_CR81","first-page":"45","volume":"3","author":"DL Gardiner","year":"2015","unstructured":"Gardiner DL, Trenholme KR. Plasmodium falciparum gametocytes: playing hide and seek. Ann Transl Med. 2015;3:45.","journal-title":"Ann Transl Med."},{"key":"3235_CR82","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1475-2875-7-125","volume":"7","author":"LC Okell","year":"2008","unstructured":"Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J. 2008;7:125.","journal-title":"Malar J."},{"key":"3235_CR83","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jit077","volume":"207","author":"P Sawa","year":"2013","unstructured":"Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis. 2013;207:1637\u201345.","journal-title":"J Infect Dis"},{"key":"3235_CR84","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1371\/journal.pmed.0050226","volume":"5","author":"LC Okell","year":"2008","unstructured":"Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 2008;5:e226.","journal-title":"PLoS Med."},{"key":"3235_CR85","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1128\/AAC.00325-13","volume":"57","author":"MJ Delves","year":"2013","unstructured":"Delves MJ, Ruecker A, Straschil U, Leli\u00e8vre J, Marques S, L\u00f3pez-Barrag\u00e1n MJ, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother. 2013;57:3268\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"3235_CR86","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1017\/S003118201400033X","volume":"141","author":"M Betson","year":"2014","unstructured":"Betson M, Sousa-Figueiredo JC, Atuhaire A, Arinaitwe M, Adriko M, Mwesigwa G, et al. Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology. 2014;141:1880\u201390.","journal-title":"Parasitology"},{"key":"3235_CR87","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12936-019-2645-x","volume":"18","author":"SD Otienoburu","year":"2019","unstructured":"Otienoburu SD, Suay I, Garcia S, Thomas NV, Srisutham S, Bj\u00f6rkman A, et al. An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT partner drug molecular surveyor. Malar J. 2019;18:12.","journal-title":"Malar J."},{"key":"3235_CR88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1051\/parasite\/2018021","volume":"25","author":"M Ouji","year":"2018","unstructured":"Ouji M, Augereau J, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.","journal-title":"Parasite."},{"key":"3235_CR89","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/1475-2875-11-408","volume":"11","author":"P Lee","year":"2012","unstructured":"Lee P, Ji D, Liu C, Rampao HS, Rosario VE, Lin I. Application of loop-mediated isothermal amplification for malaria diagnosis during a follow-up study in S\u00e3o Tom\u00e9. Malar J. 2012;11:408.","journal-title":"Malar J."},{"key":"3235_CR90","volume-title":"Defining and validating a measure of parasite resistance to sulfadoxine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (SP-IPTi)","author":"WHO","year":"2009","unstructured":"WHO. Defining and validating a measure of parasite resistance to sulfadoxine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (SP-IPTi). Geneva: World Health Organization; 2009."},{"key":"3235_CR91","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/s41598-017-06708-9","volume":"7","author":"LC Okell","year":"2017","unstructured":"Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamnine resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017;7:7389.","journal-title":"Sci Rep."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03235-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T20:16:05Z","timestamp":1618949765000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03235-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3235"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03235-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"15 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they do not have any competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}